APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Melanoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Metastatic Melanoma Drug Market Analysis and Forecast 2026-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchMetastatic Melanoma Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Melanoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Metastatic Melanoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Melanoma Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Melanoma Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metastatic Melanoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Metastatic Melanoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Metastatic Melanoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Metastatic Melanoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Metastatic Melanoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Metastatic Melanoma Drug include Novartis AG, Merck & Co., Inc., Pfizer Inc., Plexxikon Inc., Philogen S.p.A., Pharmis Biofarmaceutica, Lda., Ono Pharmaceutical Co., Ltd., OncoSec Medical Inc. and Oncolytics Biotech Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Metastatic Melanoma Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Metastatic Melanoma Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Metastatic Melanoma Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metastatic Melanoma Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Metastatic Melanoma Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Metastatic Melanoma Drug sales, projected growth trends, production technology, application and end-user industry.

Metastatic Melanoma Drug Segment by Company

Novartis AG

Merck & Co., Inc.

Pfizer Inc.

Plexxikon Inc.

Philogen S.p.A.

Pharmis Biofarmaceutica, Lda.

Ono Pharmaceutical Co., Ltd.

OncoSec Medical Inc.

Oncolytics Biotech Inc.

Omeros Corporation

NewLink Genetics Corporation

Morphotek, Inc.

Millennium Pharmaceuticals, Inc.

Merck KGaA

Metastatic Melanoma Drug Segment by Type

AGI-134

ALT-801

ALT-803

AMG-232

Others

Metastatic Melanoma Drug Segment by Application

Hospital

Clinic

Others

Metastatic Melanoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Melanoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Melanoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Melanoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Metastatic Melanoma Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Metastatic Melanoma Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metastatic Melanoma Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Metastatic Melanoma Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. AGI-134 Major Manufacturers Table 3. ALT-801 Major Manufacturers Table 4. ALT-803 Major Manufacturers Table 5. AMG-232 Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Metastatic Melanoma Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Manufacturers Table 9. Clinic Major Manufacturers Table 10. Others Major Manufacturers Table 11. Metastatic Melanoma Drug Industry Trends Table 12. Metastatic Melanoma Drug Industry Drivers Table 13. Metastatic Melanoma Drug Industry Opportunities and Challenges Table 14. Metastatic Melanoma Drug Industry Restraints Table 15. Global Metastatic Melanoma Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Metastatic Melanoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Metastatic Melanoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Metastatic Melanoma Drug Revenue Market Share by Region (2021-2026) Table 19. Global Metastatic Melanoma Drug Revenue Market Share by Region (2027-2032) Table 20. Global Metastatic Melanoma Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 21. Global Metastatic Melanoma Drug Sales by Region (2021-2026) & (W Units) Table 22. Global Metastatic Melanoma Drug Sales by Region (2027-2032) & (W Units) Table 23. Global Metastatic Melanoma Drug Sales Market Share by Region (2021-2026) Table 24. Global Metastatic Melanoma Drug Sales Market Share by Region (2027-2032) Table 25. Global Metastatic Melanoma Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Metastatic Melanoma Drug Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Metastatic Melanoma Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Metastatic Melanoma Drug Sales Market Share by Manufacturers (2021-2026) Table 29. Global Metastatic Melanoma Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Metastatic Melanoma Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Metastatic Melanoma Drug Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Metastatic Melanoma Drug Manufacturers, Product Type & Application Table 33. Global Metastatic Melanoma Drug Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Metastatic Melanoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Metastatic Melanoma Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Metastatic Melanoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Metastatic Melanoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Metastatic Melanoma Drug Revenue Market Share by Type (2021-2026) Table 40. Global Metastatic Melanoma Drug Revenue Market Share by Type (2027-2032) Table 41. Global Metastatic Melanoma Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 42. Global Metastatic Melanoma Drug Sales by Type (2021-2026) & (W Units) Table 43. Global Metastatic Melanoma Drug Sales by Type (2027-2032) & (W Units) Table 44. Global Metastatic Melanoma Drug Sales Market Share by Type (2021-2026) Table 45. Global Metastatic Melanoma Drug Sales Market Share by Type (2027-2032) Table 46. Global Metastatic Melanoma Drug Price by Type (2021-2026) & (US$/Unit) Table 47. Global Metastatic Melanoma Drug Price by Type (2027-2032) & (US$/Unit) Table 48. Global Metastatic Melanoma Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Metastatic Melanoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Metastatic Melanoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Metastatic Melanoma Drug Revenue Market Share by Application (2021-2026) Table 52. Global Metastatic Melanoma Drug Revenue Market Share by Application (2027-2032) Table 53. Global Metastatic Melanoma Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 54. Global Metastatic Melanoma Drug Sales by Application (2021-2026) & (W Units) Table 55. Global Metastatic Melanoma Drug Sales by Application (2027-2032) & (W Units) Table 56. Global Metastatic Melanoma Drug Sales Market Share by Application (2021-2026) Table 57. Global Metastatic Melanoma Drug Sales Market Share by Application (2027-2032) Table 58. Global Metastatic Melanoma Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Metastatic Melanoma Drug Price by Application (2027-2032) & (US$/Unit) Table 60. Novartis AG Company Information Table 61. Novartis AG Business Overview Table 62. Novartis AG Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Novartis AG Metastatic Melanoma Drug Product Portfolio Table 64. Novartis AG Recent Development Table 65. Merck & Co., Inc. Company Information Table 66. Merck & Co., Inc. Business Overview Table 67. Merck & Co., Inc. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio Table 69. Merck & Co., Inc. Recent Development Table 70. Pfizer Inc. Company Information Table 71. Pfizer Inc. Business Overview Table 72. Pfizer Inc. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Pfizer Inc. Metastatic Melanoma Drug Product Portfolio Table 74. Pfizer Inc. Recent Development Table 75. Plexxikon Inc. Company Information Table 76. Plexxikon Inc. Business Overview Table 77. Plexxikon Inc. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio Table 79. Plexxikon Inc. Recent Development Table 80. Philogen S.p.A. Company Information Table 81. Philogen S.p.A. Business Overview Table 82. Philogen S.p.A. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio Table 84. Philogen S.p.A. Recent Development Table 85. Pharmis Biofarmaceutica, Lda. Company Information Table 86. Pharmis Biofarmaceutica, Lda. Business Overview Table 87. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio Table 89. Pharmis Biofarmaceutica, Lda. Recent Development Table 90. Ono Pharmaceutical Co., Ltd. Company Information Table 91. Ono Pharmaceutical Co., Ltd. Business Overview Table 92. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio Table 94. Ono Pharmaceutical Co., Ltd. Recent Development Table 95. OncoSec Medical Inc. Company Information Table 96. OncoSec Medical Inc. Business Overview Table 97. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio Table 99. OncoSec Medical Inc. Recent Development Table 100. Oncolytics Biotech Inc. Company Information Table 101. Oncolytics Biotech Inc. Business Overview Table 102. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio Table 104. Oncolytics Biotech Inc. Recent Development Table 105. Omeros Corporation Company Information Table 106. Omeros Corporation Business Overview Table 107. Omeros Corporation Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Omeros Corporation Metastatic Melanoma Drug Product Portfolio Table 109. Omeros Corporation Recent Development Table 110. NewLink Genetics Corporation Company Information Table 111. NewLink Genetics Corporation Business Overview Table 112. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio Table 114. NewLink Genetics Corporation Recent Development Table 115. Morphotek, Inc. Company Information Table 116. Morphotek, Inc. Business Overview Table 117. Morphotek, Inc. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio Table 119. Morphotek, Inc. Recent Development Table 120. Millennium Pharmaceuticals, Inc. Company Information Table 121. Millennium Pharmaceuticals, Inc. Business Overview Table 122. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio Table 124. Millennium Pharmaceuticals, Inc. Recent Development Table 125. Merck KGaA Company Information Table 126. Merck KGaA Business Overview Table 127. Merck KGaA Metastatic Melanoma Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Merck KGaA Metastatic Melanoma Drug Product Portfolio Table 129. Merck KGaA Recent Development Table 130. North America Metastatic Melanoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 131. North America Metastatic Melanoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 132. North America Metastatic Melanoma Drug Sales by Type (2021-2026) & (W Units) Table 133. North America Metastatic Melanoma Drug Sales by Type (2027-2032) & (W Units) Table 134. North America Metastatic Melanoma Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 135. North America Metastatic Melanoma Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 136. North America Metastatic Melanoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 137. North America Metastatic Melanoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 138. North America Metastatic Melanoma Drug Sales by Application (2021-2026) & (W Units) Table 139. North America Metastatic Melanoma Drug Sales by Application (2027-2032) & (W Units) Table 140. North America Metastatic Melanoma Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 141. North America Metastatic Melanoma Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 142. North America Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America Metastatic Melanoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. North America Metastatic Melanoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. North America Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 146. North America Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 147. North America Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 148. North America Metastatic Melanoma Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 149. North America Metastatic Melanoma Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 150. United States Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 151. Canada Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 152. Mexico Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 153. Europe Metastatic Melanoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 154. Europe Metastatic Melanoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 155. Europe Metastatic Melanoma Drug Sales by Type (2021-2026) & (W Units) Table 156. Europe Metastatic Melanoma Drug Sales by Type (2027-2032) & (W Units) Table 157. Europe Metastatic Melanoma Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 158. Europe Metastatic Melanoma Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 159. Europe Metastatic Melanoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 160. Europe Metastatic Melanoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 161. Europe Metastatic Melanoma Drug Sales by Application (2021-2026) & (W Units) Table 162. Europe Metastatic Melanoma Drug Sales by Application (2027-2032) & (W Units) Table 163. Europe Metastatic Melanoma Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 164. Europe Metastatic Melanoma Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 165. Europe Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. Europe Metastatic Melanoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 167. Europe Metastatic Melanoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 168. Europe Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 169. Europe Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 170. Europe Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 171. Europe Metastatic Melanoma Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 172. Europe Metastatic Melanoma Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 173. Germany Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 174. France Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 175. U.K. Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 176. Italy Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 177. Russia Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 178. Spain Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 179. Netherlands Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 180. Switzerland Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 181. Sweden Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 182. Poland Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 183. China Metastatic Melanoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 184. China Metastatic Melanoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 185. China Metastatic Melanoma Drug Sales by Type (2021-2026) & (W Units) Table 186. China Metastatic Melanoma Drug Sales by Type (2027-2032) & (W Units) Table 187. China Metastatic Melanoma Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 188. China Metastatic Melanoma Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 189. China Metastatic Melanoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 190. China Metastatic Melanoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 191. China Metastatic Melanoma Drug Sales by Application (2021-2026) & (W Units) Table 192. China Metastatic Melanoma Drug Sales by Application (2027-2032) & (W Units) Table 193. China Metastatic Melanoma Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 194. China Metastatic Melanoma Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 195. Asia Metastatic Melanoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 196. Asia Metastatic Melanoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 197. Asia Metastatic Melanoma Drug Sales by Type (2021-2026) & (W Units) Table 198. Asia Metastatic Melanoma Drug Sales by Type (2027-2032) & (W Units) Table 199. Asia Metastatic Melanoma Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 200. Asia Metastatic Melanoma Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 201. Asia Metastatic Melanoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 202. Asia Metastatic Melanoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 203. Asia Metastatic Melanoma Drug Sales by Application (2021-2026) & (W Units) Table 204. Asia Metastatic Melanoma Drug Sales by Application (2027-2032) & (W Units) Table 205. Asia Metastatic Melanoma Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 206. Asia Metastatic Melanoma Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 207. Asia Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 208. Asia Metastatic Melanoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 209. Asia Metastatic Melanoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 210. Asia Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 211. Asia Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 212. Asia Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 213. Asia Metastatic Melanoma Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 214. Asia Metastatic Melanoma Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 215. Japan Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 216. South Korea Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 217. India Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 218. Australia Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 219. Taiwan Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 220. Southeast Asia Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 221. SAMEA Metastatic Melanoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 222. SAMEA Metastatic Melanoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 223. SAMEA Metastatic Melanoma Drug Sales by Type (2021-2026) & (W Units) Table 224. SAMEA Metastatic Melanoma Drug Sales by Type (2027-2032) & (W Units) Table 225. SAMEA Metastatic Melanoma Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 226. SAMEA Metastatic Melanoma Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 227. SAMEA Metastatic Melanoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 228. SAMEA Metastatic Melanoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 229. SAMEA Metastatic Melanoma Drug Sales by Application (2021-2026) & (W Units) Table 230. SAMEA Metastatic Melanoma Drug Sales by Application (2027-2032) & (W Units) Table 231. SAMEA Metastatic Melanoma Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 232. SAMEA Metastatic Melanoma Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 233. SAMEA Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 234. SAMEA Metastatic Melanoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 235. SAMEA Metastatic Melanoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 236. SAMEA Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 237. SAMEA Metastatic Melanoma Drug Sales by Country (2021-2026) & (W Units) Table 238. SAMEA Metastatic Melanoma Drug Sales by Country (2027-2032) & (W Units) Table 239. SAMEA Metastatic Melanoma Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 240. SAMEA Metastatic Melanoma Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 241. Brazil Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 242. Argentina Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 243. Chile Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 244. Colombia Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 245. Peru Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 246. Saudi Arabia Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 247. Israel Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 248. UAE Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 249. Turkey Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 250. Iran Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 251. Egypt Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Table 252. Key Raw Materials Table 253. Raw Materials Key Suppliers Table 254. Metastatic Melanoma Drug Distributors List Table 255. Metastatic Melanoma Drug Customers List Table 256. Research Programs/Design for This Report Table 257. Authors List of This Report Table 258. Secondary Sources Table 259. Primary Sources List of Figures Figure 1. Metastatic Melanoma Drug Image Figure 2. Global Metastatic Melanoma Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Melanoma Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. AGI-134 Image Figure 5. ALT-801 Image Figure 6. ALT-803 Image Figure 7. AMG-232 Image Figure 8. Others Image Figure 9. Global Metastatic Melanoma Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Metastatic Melanoma Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Clinic Image Figure 13. Others Image Figure 14. Global Metastatic Melanoma Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Metastatic Melanoma Drug Revenue (2021-2032) & (US$ Million) Figure 16. Global Metastatic Melanoma Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Metastatic Melanoma Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Metastatic Melanoma Drug Revenue Market Share by Region (2021-2032) Figure 19. Global Metastatic Melanoma Drug Sales (2021-2032) & (W Units) Figure 20. Global Metastatic Melanoma Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 21. Global Metastatic Melanoma Drug Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Metastatic Melanoma Drug Sales YoY (2021-2032) & (W Units) Figure 23. Europe Metastatic Melanoma Drug Sales YoY (2021-2032) & (W Units) Figure 24. China Metastatic Melanoma Drug Sales YoY (2021-2032) & (W Units) Figure 25. Asia (Excluding China) Metastatic Melanoma Drug Sales YoY (2021-2032) & (W Units) Figure 26. South America, Middle East and Africa Metastatic Melanoma Drug Sales YoY (2021-2032) & (W Units) Figure 27. Global Metastatic Melanoma Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Metastatic Melanoma Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Metastatic Melanoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Metastatic Melanoma Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Metastatic Melanoma Drug Revenue Market Share by Type (2021-2032) Figure 33. Global Metastatic Melanoma Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 34. Global Metastatic Melanoma Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Metastatic Melanoma Drug Sales Market Share by Type (2021-2032) Figure 36. Global Metastatic Melanoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Metastatic Melanoma Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Metastatic Melanoma Drug Revenue Market Share by Application (2021-2032) Figure 39. Global Metastatic Melanoma Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 40. Global Metastatic Melanoma Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Metastatic Melanoma Drug Sales Market Share by Application (2021-2032) Figure 42. North America Metastatic Melanoma Drug Revenue Share by Type (2021-2032) Figure 43. North America Metastatic Melanoma Drug Sales Share by Type (2021-2032) Figure 44. North America Metastatic Melanoma Drug Revenue Share by Application (2021-2032) Figure 45. North America Metastatic Melanoma Drug Sales Share by Application (2021-2032) Figure 46. North America Metastatic Melanoma Drug Revenue Share by Country (2021-2032) Figure 47. North America Metastatic Melanoma Drug Sales Share by Country (2021-2032) Figure 48. Europe Metastatic Melanoma Drug Revenue Share by Type (2021-2032) Figure 49. Europe Metastatic Melanoma Drug Sales Share by Type (2021-2032) Figure 50. Europe Metastatic Melanoma Drug Revenue Share by Application (2021-2032) Figure 51. Europe Metastatic Melanoma Drug Sales Share by Application (2021-2032) Figure 52. Europe Metastatic Melanoma Drug Revenue Share by Country (2021-2032) Figure 53. Europe Metastatic Melanoma Drug Sales Share by Country (2021-2032) Figure 54. China Metastatic Melanoma Drug Revenue Share by Type (2021-2032) Figure 55. China Metastatic Melanoma Drug Sales Share by Type (2021-2032) Figure 56. China Metastatic Melanoma Drug Revenue Share by Application (2021-2032) Figure 57. China Metastatic Melanoma Drug Sales Share by Application (2021-2032) Figure 58. Asia Metastatic Melanoma Drug Revenue Share by Type (2021-2032) Figure 59. Asia Metastatic Melanoma Drug Sales Share by Type (2021-2032) Figure 60. Asia Metastatic Melanoma Drug Revenue Share by Application (2021-2032) Figure 61. Asia Metastatic Melanoma Drug Sales Share by Application (2021-2032) Figure 62. Asia Metastatic Melanoma Drug Revenue Share by Country (2021-2032) Figure 63. Asia Metastatic Melanoma Drug Sales Share by Country (2021-2032) Figure 64. SAMEA Metastatic Melanoma Drug Revenue Share by Type (2021-2032) Figure 65. SAMEA Metastatic Melanoma Drug Sales Share by Type (2021-2032) Figure 66. SAMEA Metastatic Melanoma Drug Revenue Share by Application (2021-2032) Figure 67. SAMEA Metastatic Melanoma Drug Sales Share by Application (2021-2032) Figure 68. SAMEA Metastatic Melanoma Drug Revenue Share by Country (2021-2032) Figure 69. SAMEA Metastatic Melanoma Drug Sales Share by Country (2021-2032) Figure 70. Metastatic Melanoma Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Metastatic Melanoma Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • AGI-134
  • ALT-801
  • ALT-803
  • AMG-232
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Plexxikon Inc.
  • Philogen S.p.A.
  • Pharmis Biofarmaceutica, Lda.
  • Ono Pharmaceutical Co., Ltd.
  • OncoSec Medical Inc.
  • Oncolytics Biotech Inc.
  • Omeros Corporation
  • NewLink Genetics Corporation
  • Morphotek, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Metastatic Melanoma Drug Market by Type
  3. 1.2.1 Global Metastatic Melanoma Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 AGI-134
  5. 1.2.3 ALT-801
  6. 1.2.4 ALT-803
  7. 1.2.5 AMG-232
  8. 1.2.6 Others
  9. 1.3 Metastatic Melanoma Drug Market by Application
  10. 1.3.1 Global Metastatic Melanoma Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Clinic
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Metastatic Melanoma Drug Market Dynamics
  1. 2.1 Metastatic Melanoma Drug Industry Trends
  2. 2.2 Metastatic Melanoma Drug Industry Drivers
  3. 2.3 Metastatic Melanoma Drug Industry Opportunities and Challenges
  4. 2.4 Metastatic Melanoma Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Metastatic Melanoma Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Metastatic Melanoma Drug Revenue by Region
  3. 3.2.1 Global Metastatic Melanoma Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Metastatic Melanoma Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Metastatic Melanoma Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Metastatic Melanoma Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Metastatic Melanoma Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Metastatic Melanoma Drug Sales by Region
  9. 3.4.1 Global Metastatic Melanoma Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Metastatic Melanoma Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Metastatic Melanoma Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Metastatic Melanoma Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Metastatic Melanoma Drug Revenue by Manufacturers
  2. 4.1.1 Global Metastatic Melanoma Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Metastatic Melanoma Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Metastatic Melanoma Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Metastatic Melanoma Drug Sales by Manufacturers
  6. 4.2.1 Global Metastatic Melanoma Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Metastatic Melanoma Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Metastatic Melanoma Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Metastatic Melanoma Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Metastatic Melanoma Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Metastatic Melanoma Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Metastatic Melanoma Drug Manufacturers, Product Type & Application
  13. 4.7 Global Metastatic Melanoma Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Metastatic Melanoma Drug Market CR5 and HHI
  16. 4.8.2 2025 Metastatic Melanoma Drug Tier 1, Tier 2, and Tier 3
5 Metastatic Melanoma Drug Market by Type
  1. 5.1 Global Metastatic Melanoma Drug Revenue by Type
  2. 5.1.1 Global Metastatic Melanoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Metastatic Melanoma Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Metastatic Melanoma Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Metastatic Melanoma Drug Sales by Type
  6. 5.2.1 Global Metastatic Melanoma Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metastatic Melanoma Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Metastatic Melanoma Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Metastatic Melanoma Drug Price by Type
6 Metastatic Melanoma Drug Market by Application
  1. 6.1 Global Metastatic Melanoma Drug Revenue by Application
  2. 6.1.1 Global Metastatic Melanoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Metastatic Melanoma Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Metastatic Melanoma Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Metastatic Melanoma Drug Sales by Application
  6. 6.2.1 Global Metastatic Melanoma Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Metastatic Melanoma Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Metastatic Melanoma Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Metastatic Melanoma Drug Price by Application
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Metastatic Melanoma Drug Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Merck & Co., Inc.
  8. 7.2.1 Merck & Co., Inc. Company Information
  9. 7.2.2 Merck & Co., Inc. Business Overview
  10. 7.2.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio
  12. 7.2.5 Merck & Co., Inc. Recent Developments
  13. 7.3 Pfizer Inc.
  14. 7.3.1 Pfizer Inc. Company Information
  15. 7.3.2 Pfizer Inc. Business Overview
  16. 7.3.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Inc. Metastatic Melanoma Drug Product Portfolio
  18. 7.3.5 Pfizer Inc. Recent Developments
  19. 7.4 Plexxikon Inc.
  20. 7.4.1 Plexxikon Inc. Company Information
  21. 7.4.2 Plexxikon Inc. Business Overview
  22. 7.4.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio
  24. 7.4.5 Plexxikon Inc. Recent Developments
  25. 7.5 Philogen S.p.A.
  26. 7.5.1 Philogen S.p.A. Company Information
  27. 7.5.2 Philogen S.p.A. Business Overview
  28. 7.5.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio
  30. 7.5.5 Philogen S.p.A. Recent Developments
  31. 7.6 Pharmis Biofarmaceutica, Lda.
  32. 7.6.1 Pharmis Biofarmaceutica, Lda. Company Information
  33. 7.6.2 Pharmis Biofarmaceutica, Lda. Business Overview
  34. 7.6.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio
  36. 7.6.5 Pharmis Biofarmaceutica, Lda. Recent Developments
  37. 7.7 Ono Pharmaceutical Co., Ltd.
  38. 7.7.1 Ono Pharmaceutical Co., Ltd. Company Information
  39. 7.7.2 Ono Pharmaceutical Co., Ltd. Business Overview
  40. 7.7.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio
  42. 7.7.5 Ono Pharmaceutical Co., Ltd. Recent Developments
  43. 7.8 OncoSec Medical Inc.
  44. 7.8.1 OncoSec Medical Inc. Company Information
  45. 7.8.2 OncoSec Medical Inc. Business Overview
  46. 7.8.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio
  48. 7.8.5 OncoSec Medical Inc. Recent Developments
  49. 7.9 Oncolytics Biotech Inc.
  50. 7.9.1 Oncolytics Biotech Inc. Company Information
  51. 7.9.2 Oncolytics Biotech Inc. Business Overview
  52. 7.9.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio
  54. 7.9.5 Oncolytics Biotech Inc. Recent Developments
  55. 7.10 Omeros Corporation
  56. 7.10.1 Omeros Corporation Company Information
  57. 7.10.2 Omeros Corporation Business Overview
  58. 7.10.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Omeros Corporation Metastatic Melanoma Drug Product Portfolio
  60. 7.10.5 Omeros Corporation Recent Developments
  61. 7.11 NewLink Genetics Corporation
  62. 7.11.1 NewLink Genetics Corporation Company Information
  63. 7.11.2 NewLink Genetics Corporation Business Overview
  64. 7.11.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio
  66. 7.11.5 NewLink Genetics Corporation Recent Developments
  67. 7.12 Morphotek, Inc.
  68. 7.12.1 Morphotek, Inc. Company Information
  69. 7.12.2 Morphotek, Inc. Business Overview
  70. 7.12.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio
  72. 7.12.5 Morphotek, Inc. Recent Developments
  73. 7.13 Millennium Pharmaceuticals, Inc.
  74. 7.13.1 Millennium Pharmaceuticals, Inc. Company Information
  75. 7.13.2 Millennium Pharmaceuticals, Inc. Business Overview
  76. 7.13.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio
  78. 7.13.5 Millennium Pharmaceuticals, Inc. Recent Developments
  79. 7.14 Merck KGaA
  80. 7.14.1 Merck KGaA Company Information
  81. 7.14.2 Merck KGaA Business Overview
  82. 7.14.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Merck KGaA Metastatic Melanoma Drug Product Portfolio
  84. 7.14.5 Merck KGaA Recent Developments
8 North America
  1. 8.1 North America Metastatic Melanoma Drug Market Size by Type
  2. 8.1.1 North America Metastatic Melanoma Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Metastatic Melanoma Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Metastatic Melanoma Drug Price by Type (2021-2032)
  5. 8.2 North America Metastatic Melanoma Drug Market Size by Application
  6. 8.2.1 North America Metastatic Melanoma Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Metastatic Melanoma Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Metastatic Melanoma Drug Price by Application (2021-2032)
  9. 8.3 North America Metastatic Melanoma Drug Market Size by Country
  10. 8.3.1 North America Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Metastatic Melanoma Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Metastatic Melanoma Drug Market Size by Type
  2. 9.1.1 Europe Metastatic Melanoma Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Metastatic Melanoma Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Metastatic Melanoma Drug Price by Type (2021-2032)
  5. 9.2 Europe Metastatic Melanoma Drug Market Size by Application
  6. 9.2.1 Europe Metastatic Melanoma Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Metastatic Melanoma Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Metastatic Melanoma Drug Price by Application (2021-2032)
  9. 9.3 Europe Metastatic Melanoma Drug Market Size by Country
  10. 9.3.1 Europe Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Metastatic Melanoma Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Metastatic Melanoma Drug Market Size by Type
  2. 10.1.1 China Metastatic Melanoma Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Metastatic Melanoma Drug Sales by Type (2021-2032)
  4. 10.1.3 China Metastatic Melanoma Drug Price by Type (2021-2032)
  5. 10.2 China Metastatic Melanoma Drug Market Size by Application
  6. 10.2.1 China Metastatic Melanoma Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Metastatic Melanoma Drug Sales by Application (2021-2032)
  8. 10.2.3 China Metastatic Melanoma Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Metastatic Melanoma Drug Market Size by Type
  2. 11.1.1 Asia Metastatic Melanoma Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Metastatic Melanoma Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Metastatic Melanoma Drug Price by Type (2021-2032)
  5. 11.2 Asia Metastatic Melanoma Drug Market Size by Application
  6. 11.2.1 Asia Metastatic Melanoma Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Metastatic Melanoma Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Metastatic Melanoma Drug Price by Application (2021-2032)
  9. 11.3 Asia Metastatic Melanoma Drug Market Size by Country
  10. 11.3.1 Asia Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Metastatic Melanoma Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Metastatic Melanoma Drug Market Size by Type
  2. 12.1.1 SAMEA Metastatic Melanoma Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Metastatic Melanoma Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Metastatic Melanoma Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Metastatic Melanoma Drug Market Size by Application
  6. 12.2.1 SAMEA Metastatic Melanoma Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Metastatic Melanoma Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Metastatic Melanoma Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Metastatic Melanoma Drug Market Size by Country
  10. 12.3.1 SAMEA Metastatic Melanoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Metastatic Melanoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Metastatic Melanoma Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Metastatic Melanoma Drug Value Chain Analysis
  2. 13.1.1 Metastatic Melanoma Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Metastatic Melanoma Drug Production Mode & Process
  6. 13.2 Metastatic Melanoma Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Metastatic Melanoma Drug Distributors
  9. 13.2.3 Metastatic Melanoma Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst